VANCOUVER, BC / ACCESSWIRE / May 8, 2019 / Viridium Pacific Group Ltd. (‘Viridium’ or the ‘Company’) (TSX-V: VIR) (OTC PINK: VIRFF) is pleased to announce its wholly owned subsidiary, Experion Biotechnologies Inc. (‘Experion’), a licensed cultivator and processing company under the Cannabis Act, recently supplied 600 clones to one of the first licensed Micro-Cultivators in Canada through a buy back option agreement.
Located in British Columbia (‘BC’), the Micro-Cultivator received 600 clones with an option for Experion to purchase the flower back under a profit-sharing agreement. Buyers of Experion’s clones are newly licensed cultivators looking for quality genetics to launch their cultivation process for both the medical and adult-use markets. Experion has supplied over 2,500 clones over the last three months to licensed cultivators throughout BC and Alberta. Under the Cannabis Act, a cultivation license can sell product to other licensed facilities allowing Experion to foster new business to business (‘B2B’) relationships and the ability to create quick strategic partnerships as the market becomes established.
Mr. Jay Garnett, Chief Executive Officer, commented, ‘Experion strongly believes in the Micro-Cultivation and Craft Growing industry, and we are excited to be supporting the participants in this sector. Partnering with new cultivators enables Experion to accomplish a myriad of goals while adding shareholder value. By offering new cultivators proven genetics, sound guidance and advice, and distribution options for their product, Experion benefits from another revenue source, increased capacity and potential expansion of our product offering in the marketplace under the Citizen Stash brand. Micro-Cultivators’ unique abilities and commitment to quality enhances the Cannabis industry, and we are proud to be working with one of the first licensed in Canada.’
Viridium Pacific Group Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivatior and processor of Cannabis, based in Mission, BC; and EFX labs, a medical products production and clinical research company based in Calgary, AB.
Viridium is invested in a portfolio of products including to address a wide spectrum of consumer needs’ including Medical, Adult-use, and Wellness and Therapeutic products.
For further information, please visit the Company’s www.viridiumpacific.com or contact
Viridium Pacific Group Ltd.
Judy-Ann Pottinger, Investor Relations
Tel: (604) 617-5290
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.
SOURCE: Viridium Pacific Group Ltd.
View source version on accesswire.com: